Profil
Randall L.
Halcomb was the founder of Terns Pharmaceuticals, Inc. (founded in 2017) where he held the title of SVP-Chemistry & Early Development from 2017 to 2019.
He also held former positions as Director-Medicinal Chemistry at Gilead Sciences, Inc., Vice President-Chemistry at Igenica Biotherapeutics, Inc., and Vice President-Medicinal Chemistry at Pliant Therapeutics, Inc. (2016-2017).
Dr. Halcomb received a doctorate degree from Yale University and an undergraduate degree from The University of Alabama.
Anciens postes connus de Randall L. Halcomb
| Sociétés | Poste | Fin |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Fondateur | 01/01/2019 |
| PLIANT THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2017 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | - |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Corporate Officer/Principal | - |
Formation de Randall L. Halcomb
| Yale University | Doctorate Degree |
| The University of Alabama | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| PLIANT THERAPEUTICS, INC. | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
